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Abstract
Introduction: Anterior-gradient 2 (AGR2) is an estrogen-responsive secreted protein. Its upregulation has been well 
documented in a number of cancers, particularly breast cancer, for which mixed data exist on the prognostic 
implications of AGR2 expression. Although emerging evidence indicates that AGR2 is associated with poor prognosis, 
its function and impact on cancer-relevant pathways have not been elucidated in breast cancer.
Methods: To investigate the biologic role of AGR2 in breast cancer, AGR2 was transiently knocked down, by using 
siRNA, in T47 D and ZR-75-1 (estrogen receptor-α (ER)-positive) and MDA-MB-231 and SK-BR-3 (ER-negative) human 
breast cancer cell lines. The impact of silencing AGR2 was evaluated in both anchorage-dependent and anchorage-
independent growth (soft agar, spheroid) assays. Cell-cycle profiles in ER-positive cell lines were determined with BrdU 
incorporation, and cell death was measured with Annexin V, JC-1, and F7-26 staining. After transiently silencing AGR2 
or stimulating with recombinant AGR2, modulation of key regulators of growth and survival pathways was assessed 
with Western blot. Combination studies of AGR2 knockdown with the antiestrogens tamoxifen and fulvestrant were 
carried out and assessed at the level of anchorage-dependent growth inhibition and target modulation (cyclin D1, ER).
Results: AGR2 knockdown inhibited growth in anchorage-dependent and anchorage-independent assays, with a 
more-pronounced effect in ER-positive cell lines. Cyclin D1 levels and BrdU incorporation were reduced with AGR2 
knockdown. Conversely, cyclin D1 was induced with recombinant AGR2. AGR2 knockdown induced cell death in ZR-
75-1 and T47 D cells, and also downregulated survivin and c-Myc. Evidence of AGR2-ER crosstalk was demonstrated by 
a reduction of ER at the protein level after transiently silencing AGR2. AGR2 knockdown in combination with fulvestrant 
or tamoxifen did not preclude the efficacy of the antiestrogens, but enhanced it. In addition, p-Src, implicated in 
tamoxifen resistance, was downregulated with AGR2 knockdown.
Conclusions: Transiently silencing AGR2 in ER-positive breast cancer cell lines inhibited cell growth and cell-cycle 
progression and induced cell death. Breast cancer drivers (ER and cyclin D1) as well as cancer-signaling nodes (pSrc, c-
Myc, and survivin) were demonstrated to be downstream of AGR2. Collectively, the data presented support the utility 
of anti-AGR2 therapy in ER-positive breast cancers because of its impact on cancer-relevant pathways.
Introduction
In the United States, one in eight women will be diag-
nosed with breast cancer in their lifetimes, and the inci-
dence is increasing worldwide [1]. Estrogen receptor-α
(ER)-positive breast cancer accounted for 75% of breast
cancer cases in the United States between 1992 and 1998
[2]. 17β-Estradiol (E2) is the ligand for ER and exerts its
a c t i o n  b y  u p r e g u l a t i n g  a  n u m b e r  o f  k e y  m e d i a t o r s ,
including cyclin D1 and c-Myc [3,4]. Cyclin D1 is overex-
pressed in >50% and amplified in 15% of breast cancer
cases [5] and acts as a mitogenic sensor [6] by responding
to oncogenes and various growth factors, including E2. It
plays a critical role in cell-cycle progression, as evidenced
by the lack of entry into S phase in the absence of cyclin
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D1 [7]. In addition, cyclin D1-deficient mice do not grow
breast tumors when induced by the oncogenes Ras and
Neu [8], further supporting cyclin D1 as a key driver in
certain breast tumors.
Because of its impact on cell-growth and -survival
pathways, E2 signaling has proven to be an efficacious
target for ER-positive breast cancer therapy. However,
approximately half of ER-positive tumors have an intrin-
sic resistance to endocrine therapy, and 30% to 40% of the
remaining responsive population will acquire resistance
to tamoxifen [9], thus necessitating the exploration of
alternative therapeutic targets.
Anterior gradient-2 (AGR2) is a secreted protein that
was originally identified to be coexpressed with ER in
breast cancer cell lines [10]. AGR2 has since been demon-
strated to be estrogen [11-13] and androgen responsive
[14], and its upregulation has been reported in a number
of cancers, including breast, lung, ovarian, gastric, pan-
creatic, esophageal, and prostate cancer [11,15-25]. Addi-
tionally, in the ER-negative breast cancer cell line, MDA-
MB-231, AGR2 was induced under serum starvation and
hypoxia [26], suggesting a role for AGR2 in physiologi-
cally relevant stress conditions. Early expression studies
have correlated AGR2 expression with a better prognosis
[18], possibly because of its positive association with ER-
positive tumors, which typically have a more-favorable
prognosis than do their ER-negative counterparts [27].
Subsequent studies have explored the ER-positive tumor
population and shown that AGR2 is inversely associated
with overall and relapse-free survival [21,25], prompting
us to ask whether AGR2 plays a critical role in more-inva-
sive ER-positive tumors.
Literature relating to the functional role of AGR2 in
cancer is limited in scope. In the premalignant Barrett
esophagus and esophageal cancer models, AGR2 overex-
pression induces colony formation and transformation
[15,28]. In the course of this investigation, the converse,
siRNA- or shRNA-mediated AGR2 knockdown, was
shown to inhibit colony and subcutaneous growth in
esophageal and pancreatic cancer models [24,28]. In
breast cancer models, overexpression of AGR2 failed to
alter tumor formation in vivo or growth rate in vitro, but,
rather, reduced cell adhesion and increased the numbers
of metastases [11]. Although the phenotypic observations
in these articles are compelling, very little signaling
downstream of AGR2 has been elucidated.
AGR2 warranted further evaluation of its biology based
collectively on its prevalence in breast cancer, its negative
correlation with patient survival within the ER-positive
breast cancer subpopulation, and literature implications
of a functional role in cancer. To evaluate the impact of
targeting AGR2 in cancer, siRNA was used to knock
down AGR2 in breast cancer cell lines that endogenously
express AGR2 at varying levels. Phenotypic effects on cell
proliferation and death, as well as modulation of key can-
cer-signaling nodes, including cyclin D1, c-Myc, p-Src,
and survivin, were observed. These pathways were con-
versely modulated on treatment of a breast cancer line
with recombinant AGR2. Combining AGR2 knockdown
with ER antagonists resulted in enhanced antiprolifera-
tive effects on ER-positive lines. Altogether, our results
demonstrate a critical role for AGR2 in breast cancer
growth and survival, identify downstream signaling of
AGR2, and thus support AGR2 as a promising oncology
target for therapeutic agents.
Materials and methods
Cell lines and chemicals
Human breast cancer cell lines T47 D, ZR-75-1, MCF-7,
MDA-MB-231, and SKBR3 were purchased from ATCC.
Cell lines were maintained per ATCC guidelines. The
cells were grown at 37°C in a humidified atmosphere with
5% CO2. The 17β-estradiol, ICI 182,780, MG132, 4-
hydroxytamoxifen were obtained from Sigma. Propidium
iodide/RNase solution was purchased from BD Biosci-
ences.
Detection of AGR2 in supernatant
Conditioned media from cell lines was collected and cen-
trifuged to remove cell debris. AGR2 was immunoprecip-
itated (IP) from 2-mL samples with Protein A/G beads,
40 μg mouse anti-AGR2 (Novus) or isotype control, and
overnight incubation. IP samples were analyzed with
Western blot (described later).
siRNA knockdown
Cells were transfected in Optimem (Gibco) containing
100 nmol/L iRNA pools by using Dharmafect 3 (Dharma-
con) for SK-BR-3 cells or Dharmafect 4 for all other cell
lines for 24 hours, according to the manufacturer's proto-
col. Invitrogen AGR2 pooled siRNA, Invitrogen stealth
negative control, KSP positive control (Dharmacon), or
Dharmacon negative control siRNA was used. To support
the effects observed after siRNA knockdown in Figures 1,
2, 3, 4, 5 and 6 as being AGR2-specific effects and not an
off-target effect of the Invitrogen siRNA reagent, addi-
tional AGR2 siRNA reagents were used. siRNA reagents
targeting distinct sequences from Ambion (Ambion
Silencer) and Dharmacon (On-Target Plus Smartpool)
were used in anchorage-dependent functional studies in
T47 D and MDA-MB-231 cells with effects similar to
those seen with the Invitrogen reagent (see Supplemen-
tary figure S1a in Additional file 1).
Cell Titer Glo viability assay
Twenty-four hours after transfection, 5 × 103 cells were
plated in black-view plates. Cell Titer Glo reagent (Pro-
mega) was added according to the manufacturer's direc-
tions 96 h after transfection. The luminescence was readVanderlaag et al. Breast Cancer Research 2010, 12:R32
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Figure 1 siRNA-mediated AGR2 knockdown affects anchorage-dependent and anchorage-independent growth in breast cancer cell lines. 
T47 D, ZR-75-1, MDA-MB-231, and SK-BR-3 cells were transfected with negative control siRNA (iNC), AGR2 siRNA (iAGR2), or untransfected (UT). KSP 
(DKSP) and its corresponding control (DNC) were used as transfection controls. Results are expressed as a ratio of untransfected cells (±SD), n = 3. (a) 
Detection of endogenous AGR2 in breast cancer cell line supernatants by IP-Western and whole-cell lysates by Western. AGR2 knockdown was con-
firmed in lysates 72 hours after transfection. β-Actin served as a loading control. (b) The impact of iAGR2 on anchorage-dependent growth was eval-
uated at 96 hours after transfection by using the Cell Titer Glo assay. Anchorage-independent growth assays were also used: (i) soft agar colony 
formation assay (c), with Alamar blue as a readout; (ii) spheroid assay (d), in which lysed spheroid LDH levels were representative of total cell number 
after 8 days; corresponding spheroid images were also captured. *P < 0.05; **P < 0.01; ***P < 0.001.
(a)
(b)
0
0.5
1
1.5
T47D ZR-75-1 MDA-MB-231 SKBR3
Cell line
N
o
r
m
a
l
i
z
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
t
o
 
U
n
t
r
e
a
t
e
d
UT
INC
IAGR2
DNC
DKSP
*
*** ** ***
*
***
(c)
0
0.5
1
1.5
T47D ZR-75-1 MDA-MB-231 SKBR3
Cell line
N
o
r
m
a
l
i
z
e
d
 
F
l
u
o
r
e
s
c
e
n
c
e
 
t
o
 
U
n
t
r
e
a
t
e
d UT
INC
IAGR2
DNC
DKSP
**
***
***
***
**
*
* **
Untreated iNC iAGR2
T47D
AGR2
-Actin
T47D ZR-75-1 MDA-MB-231 SKBr3
0
0.5
1
1.5
2
T47D ZR-75-1 MDA-MB-231 SKBR3
Cell line
N
o
r
m
a
l
i
z
e
d
 
F
l
u
o
r
e
s
c
e
n
c
e
 
t
o
 
U
n
t
r
e
a
t
e
d
UT
INC
IAGR2
DNC
DKSP * * *
* * *
(d)
AGR2
T47D       ZR-75-1 MDA-MB
-231Vanderlaag et al. Breast Cancer Research 2010, 12:R32
http://breast-cancer-research.com/content/12/3/R32
Page 4 of 15
with a multiwell plate reader (DTX 880) and an integra-
tion time of 100,000 μsec.
Soft agar colony formation assay
96-well flat-bottom plates were coated with 1% agarose.
Twenty-four hours after transfection, 5 × 102 cells/well
were added in media with a final concentration of 0.33%
agarose. After a 7-day incubation, Alamar blue (Bio-
source) was added to each well, and the fluorescence was
read by using a multiwell plate reader at 530/590 nm.
Spheroid assay
Twenty-four hours after transfection, cells were plated at
a density of 1 × 104 cells/well in 96-well round-bottom
Figure 2 AGR2 knockdown reduces cell proliferation in ER-positive breast cancer cells. Cell-cycle profiles were analyzed with BrdU incorpora-
tion. Cells were pulse-labeled with 10 μM BrdU 48 hours after transfection and analyzed for BrdU incorporation with FACS. Cells were gated on Sub 
G1, G0/G1, S, and G2/M populations. (a) T47 D, (b) ZR-75-1, (c) MDA-MB-231, and (d) SK-BR-3 cells.
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Figure 3 AGR2 knockdown induces cell death. ZR-75-1 cells were collected 96 hours after AGR2 knockdown and analyzed for cell death by mea-
suring ssDNA breaks by using the following: (a) F7-26 staining by FACS analysis, and (b) alterations in mitochondrial membrane potential by deter-
mining the ratio of JC-1red to JC-1green and represented as a ratio of the untransfected control (±SD), n = 3. MG132 and CCCP served as apoptosis and 
depolarization controls, respectively. Cell death was investigated 96 hours after AGR2 knockdown in T47 D cells by using the following: (c) annexin V 
(AV) and propidium iodide (PI) and gated on normal (AV-/PI-), necrotic (AV-/PI+), early apoptotic (AV+/PI-), and late apoptotic/necrotic (AV+/PI+) cells; 
and (d) JC-1 staining, as previously described.
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Figure 4 Target modulation of proliferation and survival proteins by AGR2. (a) Lysates 72 hours after transfection with nontargeting control 
(iNC) or AGR2 (iAGR2) were evaluated with Western blot for modulation of regulators of growth and survival. Note: Some blots may be from different 
gels run with the same set of samples. (b) ZR-75-1 cells were treated for 6 hours with BSA (5 μg/mL), Novus rhAGR2 (rhAGR2 (N)), or in-house rhAGR2 
(rhAGR2(I)), and analyzed with Western blot for cyclin D1 induction. (c) ZR-75-1 cells were plated in eight-well chamber slides and treated with 5 μg/
mL of BSA or rhAGR2 (I) for 6 hours. Cells were stained with cyclin D1, and mounting medium containing DAPI was used. Images were taken by using 
a fluorescent microscope and pseudo-colored in Adobe Photoshop. (d) Quantitation of cyclin D1 immunofluorescence images. The percentage of 
cells in each bin based on cyclin D1 intensity is represented (Bin 1, weakest staining; Bin 4, brightest staining). Results are expressed as the mean ± SD; 
n = 4.
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p l a t e s  c o a t e d  w i t h  P o l y h e m a  ( S i g m a )  a n d  g r o w n  o n  a
waver platform. The spheroids were lysed in a final con-
centration of 2% Triton X-100 after 7 days. The LDH kit
(Promega) was used according to the manufacturer's
directions for lysed spheroids and read on a plate reader
at 560/590 nm.
Cell-cycle analysis by BrdU incorporation
Cell-cycle analysis was determined by transfecting cells
with siRNA, harvesting (adherent and suspension) cells
after 48 h, and measuring BrdU incorporation, as previ-
ously described [29]. Samples were then analyzed by
using a FACSCanto (Becton Dickinson), and FlowJo was
used to quantitate the cell-cycle distribution.
Detection of cell death by Annexin V/Propidium Iodide 
staining
Cells were plated at a density of 1 × 105 cells/mL and
treated with AGR2 siRNA for 96 hours. Floating and
adherent cells were stained with Annexin V-Alexa Fluor
488 (Invitrogen), as described in the manufacturer's pro-
tocol, and resuspended in PI/RNase. Samples were run
within 30 minutes with flow cytometry, and plots were
analyzed in FlowJo.
Detection of ssDNA breaks by F7-26 staining
Detection of apoptosis was determined 96 hours after
AGR2 siRNA treatment by collection of floating and
adherent cells and fixation in 100% methanol overnight.
Cells were then stained for F7-26, as previously described
[30]. Cells were resuspended in PI/RNase solution and
analyzed by using a FACSCanto. FACS plots were ana-
lyzed in FlowJo.
Measurement of mitochondrial membrane potential by JC-1
Cells were plated at a density of 1 × 105 cells/six-well plate
and were harvested 96 hours after AGR2 siRNA treat-
ment. Cells were stained with JC-1 (Invitrogen) according
to the manufacturer's directions, including the positive-
control CCCP. Samples were analyzed by using a FACS-
Canto, and CCCP-treated samples were used to perform
standard compensation. The ratio of JC-1aggregate/JC-
1monomer  was determined by calculating the geometric
mean of PE/FITC in FlowJo and then expressed as a ratio
of the untransfected control population.
Western blot analysis
Lysates were isolated by using the RIPA buffer (Sigma)
containing phosphatase and protease inhibitors, accord-
ing to the manufacturer's directions. Western blot analy-
ses were done in 2% to 5% milk/0.05% TBS-T ween at a
dilution of 1:1,000 overnight at 4°C. Antibodies were pur-
chased from the following vendors: Novus (AGR2), Santa
Cruz Biotechnology (ER), Epitomics (cyclin D1, c-Myc),
Cell Signaling (cyclin D1, E2F1, p-Erk, Erk, p-Src, Src,
survivin). Secondary conjugated sheep anti-mouse IgG
(Amersham) and donkey anti-rabbit IgG (Amersham)
HRP antibodies were used at 1:5,000 for an hour. Blots
were developed by using chemiluminescent reagents
(Pierce). Densitometry was performed on cyclin D1, ER,
and β-actin bands by using ImagePro (NIH), and a ratio
of cyclin D1 or ER values to loading control (β-actin) val-
ues for each treatment was computed. Ratios were
expressed relative to untransfected samples from the
same time point.
Treatment of ZR-75-1 cells with E2
ZR-75-1 cells were plated at a density of 1.25 × 105 cells/
mL in RPMI containing 2% charcoal-stripped serum.
Twenty-four hours after plating, the medium was
removed, and E2 was then added at a final concentration
of 10 nM, and protein was isolated after 24 hours, as
described previously.
Cyclin D1 detection in ZR-75-1 cells treated with rhAGR2
ZR-75-1 cells were plated in six-well plates or Lab-Tek II
chamber slides (Nalge Nunc) in reduced serum and
treated with 5 μg/mL of BSA, rhAGR2 (in-house), or full-
length rhAGR2 (Novus). Protein from six-well plates was
isolated 6 hours after treatment, as described previously.
Slides were fixed 6 hours after rhAGR2 treatment with
10% neutral buffered formalin, blocked in 3% BSA + 0.5%
Triton × in PBS, incubated overnight with anti-cyclin D1
Ab (Epitomics), 1:200, and for 1 hour with Alexa 594-goat
anti-rabbit (Invitrogen), 1:500. Slides were mounted by
Figure 5 Evidence of ER-AGR2 crosstalk. (a) ZR-75-1 cells were 
treated with vehicle control (DMSO) or E2 (10 nM) for 24 hours ana-
lyzed with Western blot. Numbers above bands represent relative 
AGR2 induction with E2 treatment after quantitation and normalized 
to β-actin (Image J). (b) Lysates 72 hours after AGR2 knockdown were 
analyzed with Western blot for ER. **P < 0.01. Note: Some blots may be 
from different gels run with the same set of samples.
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Figure 6 ER-independent activities after AGR2 knockdown. T47 D cells were transfected with iNC or iAGR2, and after 24 hours, cells were treated 
in combination with 4-hydroxytamoxifen (4-OHT) or ICI 182,780 (ICI) at doses of 100 nM or 1 μM. The growth-inhibitory effects of combination treat-
ments were assessed with Cell Titer Glo 96 hours after transfection (a), or the level of target modulation at 72 hours with Western blot analysis (b). (c) 
Modulation of p-Src was analyzed 72 hours after AGR2 knockdown. The kinetics of cyclin D1 and ER modulation were determined with Western blot, 
and densitometric values of cyclin D1 and ER were calculated and normalized to β-actin (Image J) and represented as the mean ± SD, n = 3. *P < 0.05; 
**P < 0.01; ***P < 0.001, antiestrogen and AGR2 knockdown combination versus AGR2 knockdown alone. Note: Some blots may be from different gels 
run with the same set of samples.
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using Pro-Long Gold with DAPI, and the slides were
imaged with a fluorescent microscope (Leica). Quantita-
tion of cyclin D1 intensity was performed by using
ImagePro by generating a DAPI-based nuclear map and
determining the relative cyclin D1 intensity per nucleus,
which was subsequently separated into four bins based
on relative intensity. In-house rhAGR2 was purified from
mammalian HEK293E cells overexpressing N-terminal
His-tagged recombinant AGR2.
E2 and/or antiestrogen treatment
T47 D cells were plated at a density of 1 × 105 cells/mL in
10% charcoal-stripped RPMI and transfected, as previ-
ously described. At 24 hours after transfection, the
medium was changed to 5% charcoal-stripped RPMI, and
cells for functional assays were replated at a density of 3 ×
103 cells/well for Cell Titer Glo and treated with vehicle,
E2, or antiestrogens. Protein was isolated 72 hours after
transfection, and phenotype plates were assayed 96 to 120
hours after transfection.
Generation of monoclonal rat anti-AGR2 Ab and test of AGR2 
Ab specificity and cross-reactivity by ELISA
One Lewis rat was immunized with human recombinant
AGR2 generated in-house for 4 months. The inguinal and
popliteal nodes were subsequently harvested and fused
with electrofusion by using Cyto PulseSciences Model
PA-101C Electrofusion System. To test for specificity and
cross-reactivity, mouse AGR2, human AGR2, and AGR3
ELISAs were used. Plates were coated with in-house
human AGR2, human AGR3, or mouse AGR2 at 0.5 μg/
mL (50 μL total volume in PBS) overnight at 4°C. Super-
natant from fusions (50 μL) were incubated on coated
plates for 1 hour at room temperature, followed by
1:2,000 of goat anti-rat HRP Ab (Jackson Laboratories)
for 30 minutes at room temperature. ABTS (50 μL/well)
was added to wells and incubated for 10 minutes at room
temperature. Absorbance was read at 405 nm.
Anti-AGR2 Ab treatment of T47 D cells
Cells were plated in 96-well flat-bottom plates at 1,000
cells/well for growth assays or Lab-Tek II chamber slides
i n  l o w  ( 2 % )  s e r u m  f o r  c y c l i n  D 1  i m m u n o f l u o r e s c e n c e
studies. Cells plated in chamber slides were treated with
the rat anti-AGR2 Ab generated in-house twice in a 48-
hour period at a concentration of 10 μg/mL and stained
for cyclin D1, as previously described. For growth studies,
48 hours after plating, antibodies were added to 96-well
plates at a final concentration of 20 μg/ml. After an addi-
tional 5 days of incubation, MTT Reagent (Roche) was
added according to the manufacturer's instructions. After
4 hours, Lysis Buffer was added, and plates were incu-
bated an additional 24 hours. Plates were read by using a
multiwell plate reader at 550/690 nm.
Statistical analysis
A two-tailed Student t test was used for statistical analy-
sis of comparative data by using GraphPad Prism. Data
were expressed as means of at least three independent
experiments ± SD, with P < 0.05 considered statistically
significant.
Results
AGR2 knockdown in breast cancer cells affects anchorage-
dependent and anchorage-independent growth
Previous reports have shown that knocking down AGR2
has an impact on growth in esophageal and pancreatic
cancer cell lines [24,28]. The role of endogenous AGR2 in
breast cancer cell proliferation was assessed with anchor-
age-dependent and anchorage-independent growth
assays. Four breast cancer cell lines, two ER-positive (T47
D and ZR-75-1) and two ER-negative (MDA-MB-231,
SK-BR-3), were used. All cell lines were transiently trans-
fected with siControl and siAGR2. Endogenous AGR2
expression was detected in cell-line supernatants and
whole-cell lysates (Figure 1a), and knockdown of AGR2
protein (Figure 1a, right) was confirmed up to 96 hours
after transfection (Supplementary figure S1b in Addi-
tional file 1). Silencing AGR2 inhibited anchorage-depen-
dent proliferation and anchorage-independent spheroid
growth only in ER-positive cell lines (Figure 1b, d). Simi-
lar results on anchorage-dependent growth in ER-posi-
tive T47 D and ER-negative MDA-MB-231 cells were
obtained by using multiple AGR2 siRNA reagents that
targeted distinct sequences (Supplementary figure S1a in
Additional file 1). In all four cell lines, AGR2 knockdown
inhibited anchorage-independent growth in the soft agar
assay (Figure 1c). Collectively, these data demonstrate
that AGR2 knockdown has a negative impact on anchor-
age-dependent and anchorage-independent growth that
is more pronounced in ER-positive breast cancer cells.
AGR2 knockdown has an impact on cell cycle and induces 
cell death
To determine whether the phenotype from Figure 1 was a
result of growth inhibition or cell death or both, cell-cycle
profiles and apoptosis/necrosis assays were used. In T47
D and ZR-75-1 cells, transient knockdown of AGR2 sig-
nificantly reduced the percentage of cells in S phase >40%
and increased the percentage of cells in G0/G1 phase com-
pared with the transfection control (Figure 2a, b). By con-
trast, treatment with siAGR2 in the two ER-negative cell
lines, MDA-MB-231 and SK-BR-3 cells, failed to alter the
cell-cycle profile compared with control cells (Figure 2c,
d).
Transient knockdown of AGR2 in ZR-75-1 cells yielded
an 11% increase in F7-26 staining, indicative of single-
stranded DNA breaks and apoptosis (Figure 3a). An
apoptotic phenotype with AGR2 knockdown in ZR-75-1
cells was further supported by an observed depolariza-
tion of the mitochondrial membrane, established by
using JC-1 staining, that was comparable to the apopto-
sis-inducing control, MG132 (Figure 3b). By contrast, inVanderlaag et al. Breast Cancer Research 2010, 12:R32
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T47 D cells, AGR2 silencing increased the percentage of
the propidium-iodide-only cell population >7% above
both the negative control and the apoptosis control,
which is indicative of necrosis. Although the increase in
propidium iodide staining was moderate, we consistently
observed this result (n = 3). The Annexin V-positive pop-
ulation was only slightly higher compared with control
samples after AGR2 knockdown (Figure 3c). In T47 D
cells, JC-1 staining indicated a hyperpolarization of the
mitochondrial membrane after knocking down AGR2
(Figure 3d), which is required for distinct stages of both
apoptosis and necrosis [31]. In apoptosis, hyperpolariza-
tion occurs early and is followed by depolarization, which
was not observed at later times in siAGR2-treated T47 D
cells (Supplementary figure S2b in Additional file 2),
whereas sustained hyperpolarization has been reported
to sensitize cells to necrosis [32]. Furthermore, consistent
with necrotic, nonapoptotic cell death in T47 D cells, no
increase was found in the F7-26-positive population after
AGR2 knockdown (Supplementary figure S2a in Addi-
tional file 2). Based on BrdU incorporation and death
assays, AGR2 knockdown in ER-positive, but not ER-neg-
ative, cells reduces cell proliferation and induces cell con-
text-dependent death.
AGR2 modulates critical regulators of cell growth and 
survival
To dissect the signaling associated with the cell-death and
cell-cycle phenotypes observed in Figures 2 and 3, the
impact of AGR2 knockdown on critical regulators of
these pathways was assayed with Western blot. In T47 D
and ZR-75-1 cells, the protein c-Myc and the antiapop-
totic protein survivin were reduced after AGR2 knock-
down (Figure 4a), consistent with the cell-death effects
observed in Figure 3. To a lesser degree, survivin was also
downregulated in SK-BR-3 cells treated with siAGR2.
Because knockdown of AGR2 in ER-positive cells yielded
an accumulation of cells in G0/G1, key regulators of this
phase of the cell cycle were assayed with Western blot in
these cell types. Interestingly, in all four cell types tested,
cyclin D1 protein was downregulated with AGR2 silenc-
ing (Figure 4a). In addition, E2F1 was downregulated in
T47 D, ZR-75-1, and MDA-MB-231 and was also consis-
tently downregulated to a modest degree in SK-BR-3 cells
(n = 3). Given that AGR2 is secreted (Figure 1), we asked
whether it could act extracellularly. When ZR-75-1 cells
were treated with recombinant AGR2 (Figure 4b-d),
cyclin D1 was induced, beyond already significant levels,
confirming that cyclin D1 is downstream of AGR2.
Evidence of AGR2-ER crosstalk
Previous studies showed that E2 treatment in MCF-7
cells induces AGR2 at the message level [11]. Consistent
with AGR2 responsiveness to E2, E2 treatment in ZR-75-
1 cells further induced AGR2 at the protein level (Figure
5a). We subsequently investigated potential crosstalk
between AGR2 and ER because E2 signaling affects the
cell cycle, c-Myc, and cyclin D1 [33], which are also mod-
u l a t e d  w i t h  A G R 2  k n o c k d o w n .  N o t a b l y ,  n u m e r o u s
reports have been made of ER crosstalk with other path-
ways [34-36]. To determine whether AGR2 could con-
versely affect E2 signaling, ER levels were assessed after
AGR2 knockdown. In ER-positive cells, silencing of
AGR2 yielded a reduction of ER protein (Figure 5b). In
T47 D cells, a double band for ER was detected, which
may be due to a phosphorylated form of the protein. Col-
lectively, these data suggest that E2 can affect AGR2 pro-
tein levels, and, conversely, knockdown of AGR2 can lead
to a reduction in ER protein levels.
AGR2 biology involves ER-dependent and ER-independent 
mechanisms
Much of the AGR2 biology shown thus far might be tied
to an impact on ER and subsequent downstream signal-
ing. The partial antiestrogen, tamoxifen, and 'pure' anties-
trogen, fulvestrant--first-line treatments for ER-positive
patients--both modulate the cell cycle and reduce cyclin
D1 and c-Myc levels [33]. In addition, in a fashion similar
to AGR2 knockdown, ER is downregulated by fulvestrant.
Therefore, we wanted to determine how AGR2 knock-
down might affect antiestrogen activity. Phenotypically,
AGR2 knockdown augmented the degree of growth inhi-
bition when combined with either antiestrogen (Figure
6a). At the level of target modulation, silencing AGR2 in
combination with antiestrogens further enhanced ER and
cyclin D1 downregulation (Figure 6b, compare lane 6
with lanes 9 and 12). This suggests that an anti-AGR2
therapy would not preclude the activity of an antiestro-
gen, and the combination might be advantageous.
Tamoxifen treatment in MCF-7 cells has been reported
to elevate Src phosphorylation levels and is associated
with acquired tamoxifen resistance [37]. Recently, target-
ing both Src and ER has been shown to prevent acquired
resistance to tamoxifen therapy [38]. To determine
whether inhibiting AGR2 activity might affect this resis-
tance-associated protein, phosphorylation of Src was
examined. Silencing AGR2 downregulated p-Src, but not
total Src levels, in both ER-positive breast cancer cell
lines (Figure 6c).
Because cyclin D1 is a downstream target of E2 signal-
ing, we sought to determine whether cyclin D1 modula-
tion by AGR2 could be tied exclusively to an impact on
ER. The kinetics of AGR2 knockdown was assessed at 24,
32, and 48 hours. Cyclin D1 was downregulated after 24
hours, whereas ER was downregulated at 32 hours (Fig-
ure 6d), indicating that cyclin D1 downregulation was at
least, in part, due to an ER-independent mechanism. This
is also consistent with the cyclin D1 downregulation
observed in ER-negative cell lines (Figure 4a).Vanderlaag et al. Breast Cancer Research 2010, 12:R32
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Anti-AGR2 Ab modulates cyclin D1 and inhibits cell growth
Although the induction of cyclin D1 protein with recom-
binant AGR2 suggested that AGR2 can act extracellularly
(Figure 4c), given that Park et al. [39] had shown that
A G R 2  i s  a n  e n d o p l a s m i c  r e t i c u l u m  p r o t e i n ,  w e  a s k e d
whether AGR2 activity could be inhibited extracellularly.
Monoclonal antibodies raised in rats immunized with
recombinant AGR2 were assayed for AGR2 specificity
and species cross-reactivity with ELISA. The antibody
bound both mouse and human forms of AGR2, but not
human AGR3 (Figure 7a). Cultured T47 D cells were
treated with the monoclonal Ab and compared with
AGR2 siRNA treatment for effects on cyclin D1, by using
cyclin D1 immunofluorescence staining (Figure 7b, left
panel). Images were quantitated for relative cyclin D1
intensity (Figure 7b, right panel). Consistent with West-
ern data (Figure 4a), cyclin D1 was reduced after tran-
siently silencing AGR2 by siRNA in T47 D cells. Cyclin
D1 was also significantly reduced in T47 D cells treated
with an anti-AGR2 antibody. The impact of the AGR2 Ab
on cell growth was investigated in T47 D, ZR-75-1, and
MDA-MB-231 cells. Treatment with the anti-AGR2 Ab
modestly reduced cell growth in all three cell lines (Figure
7c). In summary, the effects of the anti-AGR2 Ab suggest
that AGR2 can act extracellularly.
Discussion
AGR2 is overexpressed in a number of epithelial cancers
[11,15-25] and is inversely associated with patient sur-
vival in the ER-positive patient population [21,25].
Although this association itself does not indicate a critical
role for AGR2 in disease progression, it does warrant
examination of the functional relevance of this gene. Both
anchorage-dependent growth and anchorage-indepen-
dent growth were inhibited after silencing endogenously
expressed AGR2 in ER-positive cell lines (Figure 1). This
impact on growth was seen with multiple AGR2 siRNA
sequences (Supplementary figure S1 in Additional file 1),
which supports the specificity of the effect of AGR2
knockdown on the inhibition of cancer cell growth.
AGR2 knockdown significantly reduced colony forma-
tion in soft agar in ER-negative lines, as well (Figure 1c),
raising an interesting discrepancy between ER-positive
and ER-negative lines. The soft-agar assay represents a
particularly stressful in vitro assay, as it requires the can-
cer cells to grow from a single cell, whereas other assays
allow for cell-cell interaction. Support exists in the litera-
ture for a role of AGR2 in stress conditions [15,26].
Another possibility is that the soft-agar assay measures
AGR2-dependent biologies that are not captured in the
other assays, a concept consistent with distinct breast
cancer models, in which AGR2 overexpression was
reported to play a role in metastases and adhesion, but
not growth [11]. Aligned with the hypothesis that MDA-
MB-231 cells may be more sensitive to neutralization of
AGR2 activity under stress conditions, we observed that
our AGR2-neutralizing mAb inhibited MDA-MB-231 cell
growth under low serum conditions. As noted earlier,
siRNA-mediated knockdown of AGR2 in MDA-MB-231
cells in full-serum conditions had little growth effect in
anchorage-dependent conditions. The MDA-MB-231
cells were more sensitive to growth inhibition with the
AGR2-neutralizing mAb than were T47 D and ZR-75-1
cells, although this may be trivially explained by the
observation that MDA-MB-231 cells have significantly
lower levels of AGR2 than do T47 D and ZR-75-1 cells
used in the same experiment and thus may be more read-
ily neutralized. Although this is the first time a role for
A G R 2  h a s  b e e n  d e m o n s t r a t e d  i n  b r e a s t  c a n c e r  c e l l
growth, these results are consistent with the impact of
AGR2 knockdown on cell growth reported in other non-
breast cancer models.
To further evaluate the role of AGR2 in breast cancer,
the impact on cell death and the cell cycle were explored.
Supporting the anchorage-dependent functional data, a
cell-cycle phenotype and induction of cell death was seen
in both T47 D and ZR-75-1 cells (Figures 2 and 3). Thus
far, neither phenotype has been reported. The BrdU phe-
notype is in contrast to previous reports in which stable
expression of AGR2 in H1299 cells had no effect on the
cell cycle or DNA synthesis [15]. Cell context-dependent
differences exist in the mechanisms of cell death, which
may be related to the genetic background of the respec-
tive cell lines, such as the differences in p53 status, but
cell death was observed in either case. That inhibition of
AGR2 activity can induce cytotoxicity, in addition to
being cytostatic, is particularly important for the poten-
tial to treat slow-growing tumors.
To provide support for the phenotypic effects shown
with AGR2 knockdown and to understand AGR2 biology
in greater depth, we investigated intracellular signaling
downstream of AGR2. Mechanistic hints from the litera-
ture have been limited to a role for AGR2 in the wild-type
p53 transcriptional response [15]. Because T47 D cells
have mutated p53, and ZR-75-1 cells have wild-type p53,
and a phenotype with AGR2 knockdown was observed in
both, AGR2 biology cannot be limited to the p53 path-
way. Cell-cycle modulation and induction of cell death
after transient knockdown of AGR2 directed us to
explore other signaling pathways that may be relevant to
AGR2 biology. Modulation of cyclin D1, c-Myc, and E2F1
by AGR2 knockdown is consistent with the cell-cycle and
anchorage-dependent growth phenotype seen in the ER-
positive cell lines. The impact of AGR2 knockdown on
cyclin D1 in ER-negative cell lines that did not translate
into a cell-cycle phenotype was an intriguing result. Sev-
eral possibilities could account for this observation. It
could also be a threshold issue, requiring that a certainVanderlaag et al. Breast Cancer Research 2010, 12:R32
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Figure 7 Impact of rat anti-AGR2 Ab on cell growth and cyclin D1 in T47 D cells. (a) Rat anti-AGR2 Abs were tested for AGR2 specificity by using 
an ELISA directed against human AGR2 and human AGR3. Species crossreactivity also was assessed by using an ELISA directed against mouse AGR2. 
(b) After confirming Ab specificity, T47 D cells were treated with an anti-AGR2 Ab (10 μg/mL) for 48 hours or AGR2 siRNA for 72 hours, and cyclin D1 
modulation was examined with immunofluorescence. Cells were stained with cyclin D1, and mounting media containing DAPI were used. Images 
were taken by using a fluorescence microscope and pseudo-colored in Adobe Photoshop. The isotype control Ab used for cyclin D1 staining was an 
anti-AGR2 Ab of the same isotype but was not shown to modulate cyclin D1 or to have an impact on growth. Cyclin D1 intensity was quantitated by 
using ImagePro and binned based on intensity, and the percentage of cells in each bin based on cyclin D1 intensity is represented (Bin 1, weakest 
staining; Bin 4, brightest staining). (c) T47 D, ZR-75-1, and MDA-MB-231 cells were treated for 5 days with 20 μg/mL anti-AGR2 Ab. The relative number 
of cells was quantitated by using the MTT assay. Results are expressed relative to untreated sample for each cell line.
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percentage of cyclin D1 be downregulated to result in a
phenotype similar to that observed in ER-positive cells. It
is of note that cyclin D1 can be downregulated through
both ER-dependent and ER-independent pathways. In
addition, ZR-75-1 cells have cyclin D1 amplified and are
known to be driven by cyclin D1 [40], which may not be
so important a driver in the ER-negative cell types tested.
Collectively, downregulation of cyclin D1 in all four cell
types after AGR2 knockdown or treatment with an anti-
AGR2 Ab supports cyclin D1 being downstream of
AGR2.
We also provide evidence that AGR2 can act extracellu-
larly. This finding is in contrast to a recent report suggest-
ing that AGR2, a member of the protein disulfide
isomerase family, is localized in the endoplasmic reticu-
lum and plays an essential role for mucus production
[39]. Because cyclin D1 is induced with an exogenous
source of AGR2 (Figure 4) and reduced with an anti-
AGR2 Ab (Figure 7), and AGR2 is detected in the super-
natant of breast cancer cell lines, it suggests that AGR2
may have an extracellular mechanism of action. Consis-
tent with our data, other disulfide isomerases have also
been associated with cancer-relevant biologies, including
invasiveness and stress survival [41,42].
To provide further evidence that AGR2 is important in
breast cancer progression, silencing AGR2 in ER-positive
cells downregulated c-Myc, p-Src, and survivin. All of
these molecules play critical roles in breast cancer pro-
gression by affecting growth, survival, angiogenesis,
migration, and invasion [43], and hence are individually
being investigated as targeted monotherapies [44,45].
Given the high level of biologic relevance of p-Src, sur-
vivin, and c-Myc in cancer, modulation of these key play-
ers after silencing AGR2 suggests that AGR2 may be the
key in other cancers, beyond breast cancer.
E2 is another key driver and potent mitogen of breast
cancer. Several articles in the literature indicate AGR2 is
an E2-responsive gene [11-13], and we similarly observed
an induction of AGR2 in E2-treated ZR-75-1 cells (Figure
5a). The more-novel finding is that ER protein levels are
reduced after AGR2 knockdown (Figure 5b). Because ER
downregulation leads to reduced estrogen responsiveness
with fulvestrant, this suggests that ER downregulation
induced by AGR2 knockdown might also negatively
influence the mitogenic activity of E2. The relative E2
responsiveness could not be accurately assessed in these
AGR2-silenced cells, given the complexity of the relations
of these molecules, because E2 itself modulates ER in T47
D cells [46].
Given the similar profiles of AGR2 knockdown with E2
signaling, important considerations existed when assess-
ing the potential crosstalk between the ER and AGR2
pathways. Initially, we asked how AGR2 knockdown
would affect the effect of antiestrogens on cancer cell
lines. Next, we determined whether AGR2 might have
ER-independent activities. AGR2 knockdown in combi-
nation with antiestrogens did not preclude antiestrogen
efficacy, and the combination enhanced the impact on
growth, ER and cyclin D1 (Figure 6a, b). The kinetics of
AGR2 knockdown showed that cyclin D1 downregulation
occurs before ER downregulation, and therefore, AGR2
has an ER-independent pathway for downregulating
cyclin D1, which is supported by the impact on cyclin D1
seen in ER-negative cells.
Conclusions
AGR2 is commonly overexpressed in cancers, and our
data suggest an important functional role for AGR2 in
breast cancer. AGR2 affects key breast cancer drivers,
including cyclin D1, c-Myc, and ER, as well as more gen-
eral oncogenic signaling nodes such as p-Src and sur-
vivin. Removal of AGR2 has an impact on cancer-relevant
pathways, including the cell cycle and E2 signaling, ulti-
mately resulting in cell death, thus demonstrating that
AGR2 plays a critical role in breast cancer progression.
Beyond elucidating novel biology, the mechanism of
action also suggests that AGR2 would be a good thera-
peutic target because its inhibition appears to have added
benefit when combined with conventional antiestrogen
treatments. Tumors treated with tamoxifen can become
hypersensitive to E2 [47], and both an anti-AGR2 therapy
and fulvestrant address this issue because ER is downreg-
ulated with these treatments. In addition, survivin and p-
Src have been implicated in tamoxifen resistance, and
both are modulated by AGR2 knockdown. Furthermore,
an anti-AGR2 therapy, unlike fulvestrant, can potentially
function in cancers driven by cyclin D1 that can no longer
respond to E2, given the ER-independent actions of
AGR2 on cyclin D1. Collectively, the data presented sup-
port the utility of an anti-AGR2 therapy in ER-positive
breast cancers.
Additional material
Additional file 1 Supplementary figure S1. Impact of AGR2 on breast 
cancer cell growth using AGR2 siRNA from multiple vendors. (a) T47 D and 
MDA-MB-231 cells were treated with AGR2 siRNA from Invitrogen, Ambion 
and Dharmacon and their appropriate nontargeting controls. Ninety-six 
hours after transfection, Cell Titer Glo was used as a readout for relative cell 
number. Results are expressed relative to untransfected cells. (b) Whole-cell 
lysates were isolated from T47 D and MDA-MB-231 cells at 48, 72, or 96 
hours after transfection to confirm knockdown or AGR2 protein.
Additional file 2 Supplementary figure S2. Additional death assays after 
AGR2 knockdown in T47 D cells. (a) F7-26 staining, a measure of ssDNA 
breaks, was measured 96 hours after AGR2 knockdown in T47 D cells with 
fluorescence-activated cell sorting (FACS) analysis. Hydrogen peroxide was 
used as a positive control for the assay. (b) Alterations in mitochondrial 
membrane potential 120 hours after AGR2 knockdown were assessed by 
determining the ratio of JC-1red to JC-1green and are represented as a ratio of 
the untransfected control (±SD), n = 3. MG132 and CCCP served as apopto-
sis and depolarization controls, respectively.Vanderlaag et al. Breast Cancer Research 2010, 12:R32
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